MRAI

Marpai, Inc.
2 filings tracked
healthcarehealthcare administrationMICRO (<$300M)

Company Intelligence Hub

Filing history, signal momentum, and bull/bear evolution

Chronological Filing Evolution (Click to filter / toggle)

Thesis (Bull Case Evolution)

Marpai is currently navigating a high-stakes operational pivot, transitioning from a diversified insurance play to a streamlined technology-driven Third Party Administrator (TPA).…

Bullish Outlook

Antithesis (Bear Case / Structural Risks)

Despite the narrative of a turnaround, Marpai's financial foundation remains precarious. The company reports a staggering accumulated deficit of $118.6 million and is operating with a dangerously low unrestricted cash balance of just $201,000.…

Risk Factors

Read the full bull/bear analysis

You are reading the free preview. Start a free trial to unlock the complete bull & bear analysis for every MRAI filing.

Start Free Trial

Synthesis (Verdict & Resolution)

The Q1 2026 filing presents a company at a crossroads, where the ability to survive depends entirely on the execution of a strategic transaction or a fresh capital injection. The debt extension to 2028 is a critical short-term victory that prevents immediate collapse, but it does not solve the fundamental issue of negative cash flow and a shrinking revenue base. Investors are essentially betting on the intrinsic value of the TPA technology platform and the management's ability to find a buyer or partner. Ultimately, the filing confirms a 'going concern' doubt, placing Marpai in a distressed category. The trade-off for shareholders is a high-risk gamble: the potential for a value-accretive merger versus the likelihood of continued dilution and eventual default. The market will now look toward the 'strategic alternatives' mentioned by the Board to see if a viable path to solvency exists beyond the current debt restructuring.

Selected Quarter

Core Takeaway

Marpai avoided immediate default by extending its JGB debentures to 2028, but it remains critically low on unrestricted cash and faces massive liabilities.

Investor Lens

The trade-off is between the potential of a strategic buyout and the high probability of total equity wipeout due to insolvency.

Watch Next

The outcome of 'strategic alternatives' reviews and any new equity raises to replenish unrestricted cash.

Signal Momentum Chart

Quarterly net bull/bear signal ratio. Click nodes to select a quarter.

BULLISH (+1.0)NEUTRAL (0.0)BEARISH (-1.0)-0.33Q2 '26 (10-Q)

Signal Timeline

Active Filters:Quarter: Q2 '26 (10-Q)
bullishMay 15

Extended JGB debenture maturity to 2028 and secured additional personal collateral.

debt restructure
70%
bearishMay 15

Revenue declined 18% YoY with continuing net losses of $3.2 million.

earnings miss
60%
bearishMay 15

Operating losses increased slightly YoY despite cost-cutting measures.

margin compression
50%
bearishMay 15

Critical liquidity shortage and going concern warning necessitate further capital raises.

dilution risk
90%
bullishMay 15

Extended JGB debenture maturity to 2028 and secured additional personal collateral.

debt restructure
70%
bearishMay 15

Revenue declined 18% YoY with continuing net losses of $3.2 million.

earnings miss
60%
bearishMay 15

Operating losses increased slightly YoY despite cost-cutting measures.

margin compression
50%
bearishMay 15

Critical liquidity shortage and going concern warning necessitate further capital raises.

dilution risk
90%

Filing History

10-QMay 15, 2026
Expand Sequence

The Q1 2026 filing presents a company at a crossroads, where the ability to survive depends entirely on the execution of a strategic transaction or a fresh capital injection. The debt extension to 2028 is a critical short-term victory that prevents immediate collapse, but it does not solve the fundamental issue of negative cash flow and a shrinking revenue base. Investors are essentially betting on the intrinsic value of the TPA technology platform and the management's ability to find a buyer or partner. Ultimately, the filing confirms a 'going concern' doubt, placing Marpai in a distressed category. The trade-off for shareholders is a high-risk gamble: the potential for a value-accretive merger versus the likelihood of continued dilution and eventual default. The market will now look toward the 'strategic alternatives' mentioned by the Board to see if a viable path to solvency exists beyond the current debt restructuring.

Disclaimer: The synthesis provided is generated by AI models and should not be construed as investment advice. Analysis is based solely on regulatory data present at the time of publication. Consult a financial advisor for specific investment strategies.